Probiotics for the Management of Oral Mucositis: An Interpretive Review of Current Evidence

Fallah, Maryam; Amin, Negin; Moghaddasian, Mohammed H.; Jafarnejad, Sadegh

doi:10.34172/apb.2023.029

Cited by 3 publications

(1 citation statement)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hong et al also demonstrated that OM severity is associated with 5-FU [134]. Modification of oral microbiome is a promising preventive treatment for OM [135,136]. Palifermin, which is the only pharmacological agent approved by the FDA to treat OM, is a recombinant human keratinocyte growth factor (KGF) that targets the KGF receptor to enhance the differentiation and maturation of epithelial cells [132,137].…”

Section: Microbiota and Treatment Outcomes Of Osccmentioning

confidence: 99%

Mechanisms and Potential Clinical Implications of Oral Microbiome in Oral Squamous Cell Carcinoma

Wang,

Gao

2023

Current Oncology

View full text Add to dashboard Cite

Microorganisms in the oral cavity are abundant in the human body. At present, more than 700 species of oral microorganisms have been identified. Recently, a lot of literature has indicated that the oral microbiota plays an important role in the occurrence, development, and prognosis of oral squamous cell carcinoma (OSCC) through various mechanisms. And researchers are now trying to utilize oral microbiota in cancer diagnosis and treatment. However, few articles systematically summarize the effects of oral microbes in the diagnosis, treatment, and disease outcomes of oral cancer. Herein, we made a summary of the microbial changes at cancerous sites and placed more emphasis on the mechanisms by which the oral microbiome promotes cancerization. Moreover, we aimed to find out the clinical value of the oral microbiome in OSCC.

show abstract

Section: Microbiota and Treatment Outcomes Of Osccmentioning

confidence: 99%

Mechanisms and Potential Clinical Implications of Oral Microbiome in Oral Squamous Cell Carcinoma

Wang,

Gao

2023

Current Oncology

View full text Add to dashboard Cite

show abstract

What We Know About the Actual Role of Traditional Probiotics in Health and Disease

Al-Akayleh,

Agha,

Al‐Remawi

et al. 2024

Probiotics & Antimicro. Prot.

View full text Add to dashboard Cite

Preventive effect of probiotics on oral mucositis induced by anticancer therapy: a systematic review and meta-analysis of randomized controlled trials

Yang,

Li,

Shi

2024

BMC Oral Health

View full text Add to dashboard Cite

Background Oral mucositis (OM) is a prevalent and painful complication in patients undergoing anticancer treatment, which significantly impacts patients’ quality of life (QoL) and adherence to therapy. The use of oral probiotics as a preventive strategy for OM has shown promise, but the clinical evidence remains inconclusive. This meta-analysis of randomized controlled trials (RCTs) aims to evaluate the efficacy of probiotics in preventing OM caused by radiotherapy and/or chemotherapy. Methods A comprehensive search of PubMed, EMBASE, Web of Science, Cochrane Library, and ClinicalTrials.gov was conducted up to January 31, 2024, to identify eligible RCTs. The primary outcomes were the incidences of severe OM and all-grade OM. Secondary outcomes included rates of anticancer treatment completion, clinical response, requirement for enteral nutrition, time course of OM, body weight loss, QoL, and adverse events (AEs). Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated. Results A total of 12 RCTs involving 1,376 patients were included in the quantitative analysis. Probiotics administration significantly reduced the risk of severe OM (RR = 0.61, 95%CI: 0.53–0.72, P < 0.001) and all-grade OM (RR = 0.90, 95%CI: 0.82–0.98, P = 0.016) compared to the control group. Multi-strain probiotics formulations were more effective than single-strain probiotics in preventing severe OM ( P = 0.011). There were no significant differences between the probiotics and control groups regarding anticancer treatment completion (RR = 1.03, 95%CI: 0.98–1.08, P = 0.198), clinical response to therapy (RR = 1.05, 95%CI: 0.94–1.17, P = 0.406), or the need for enteral nutrition (RR = 1.28, 95%CI: 0.49–3.35, P = 0.680). AEs related to probiotics were rare, with no serious AEs attributable to probiotics use. Conclusions Oral probiotics are both safe and effective in preventing and reducing the severity of OM in patients undergoing anticancer therapy. Multi-strain probiotics demonstrate superior efficacy compared to single-strain probiotics. Further research is warranted to confirm these findings and optimize probiotic treatment strategies for cancer patients. Supplementary Information The online version contains supplementary material available at 10.1186/s12903-024-04955-7.

show abstract

Probiotics for the Management of Oral Mucositis: An Interpretive Review of Current Evidence

Cited by 3 publications

References 64 publications

Mechanisms and Potential Clinical Implications of Oral Microbiome in Oral Squamous Cell Carcinoma

Mechanisms and Potential Clinical Implications of Oral Microbiome in Oral Squamous Cell Carcinoma

What We Know About the Actual Role of Traditional Probiotics in Health and Disease

Preventive effect of probiotics on oral mucositis induced by anticancer therapy: a systematic review and meta-analysis of randomized controlled trials

Contact Info

Product

Resources

About